JACOBS LEVY EQUITY MANAGEMENT, INC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 119 filers reported holding DENALI THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.75 and the average weighting 0.7%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q2 2021$602,000
-76.7%
7,679
-83.0%
0.00%
-80.0%
Q1 2021$2,586,000
+968.6%
45,296
+288.5%
0.02%
+566.7%
Q2 2019$242,00011,6600.00%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q3 2019
NameSharesValueWeighting ↓
Crestline Management, LP 7,460,732$219,569,00028.65%
ARCH Venture Management, LLC 5,168,749$152,116,00018.54%
Casdin Capital, LLC 1,500,000$44,145,0003.73%
Flagship Pioneering Inc. 2,619,968$77,106,0002.90%
Yiheng Capital Management, L.P. 1,014,684$29,862,0001.71%
SECTORAL ASSET MANAGEMENT INC 202,100$5,948,0001.20%
GILDER GAGNON HOWE & CO LLC 1,956,820$57,589,0001.03%
Artal Group S.A. 600,000$17,658,0000.94%
Temasek Holdings (Private) Ltd 5,369,487$158,024,0020.87%
BRANDYWINE MANAGERS, LLC 9,601$283,0000.69%
View complete list of DENALI THERAPEUTICS INC shareholders